Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Equity: 2021-2025

Historic Return on Equity for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -2.81%.

  • Rhythm Pharmaceuticals' Return on Equity rose 743.00% to -2.81% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.81%, marking a year-over-year increase of 743.00%. This contributed to the annual value of -2.72% for FY2024, which is 187.00% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Return on Equity is -2.81%, which was up 94.60% from -52.01% recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Return on Equity ranged from a high of -0.16% in Q2 2021 and a low of -52.01% during Q2 2025.
  • Moreover, its 3-year median value for Return on Equity was -2.81% (2025), whereas its average is -9.12%.
  • Examining YoY changes over the last 5 years, Rhythm Pharmaceuticals' Return on Equity showed a top increase of 743bps in 2025 and a maximum decrease of 4,687bps in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Return on Equity (Quarterly) stood at -0.26% in 2021, then slumped by 41bps to -0.66% in 2022, then slumped by 34bps to -1.01% in 2023, then crashed by 1,481bps to -15.82% in 2024, then soared by 743bps to -2.81% in 2025.
  • Its Return on Equity was -2.81% in Q3 2025, compared to -52.01% in Q2 2025 and -8.30% in Q1 2025.